These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9183140)

  • 41. Severe movement disorder and psychosis from haloperidol withdrawal in a 7-year-old girl with autism.
    Syamkumar S; Dossetor D
    J Paediatr Child Health; 2021 Feb; 57(2):286-288. PubMed ID: 32162759
    [No Abstract]   [Full Text] [Related]  

  • 42. Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design.
    Cohen IL; Campbell M; Posner D; Small AM; Triebel D; Anderson LT
    J Am Acad Child Psychiatry; 1980; 19(4):665-77. PubMed ID: 7204797
    [No Abstract]   [Full Text] [Related]  

  • 43. Lack of tolerance to haloperidol-induced acute dyskinesias in rhesus monkeys.
    Porsolt RD
    Psychopharmacology (Berl); 1984; 82(1-2):145-6. PubMed ID: 6420826
    [No Abstract]   [Full Text] [Related]  

  • 44. Invitation for further observation.
    Schmid E; Satz P
    J Autism Dev Disord; 1984 Dec; 14(4):452-3. PubMed ID: 6151559
    [No Abstract]   [Full Text] [Related]  

  • 45. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
    McDougle CJ; Holmes JP; Carlson DC; Pelton GH; Cohen DJ; Price LH
    Arch Gen Psychiatry; 1998 Jul; 55(7):633-41. PubMed ID: 9672054
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Withdrawal Dyskinesia Associated With Aripiprazole in a Child: A Case Report.
    Nishijima H; Nishijima M; Oyama C; Tomiyama M
    Cureus; 2024 Jul; 16(7):e65223. PubMed ID: 39184787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of second-generation antipsychotics in autism spectrum disorder: a systematic review and meta-analysis protocol.
    Lopes LPN; de Oliveira JC; Bergamaschi CC; Fulone I; Lima EDC; Abe FC; Mazzei LG; Figueiró MF; Lopes LC
    BMJ Open; 2023 Jun; 13(6):e069114. PubMed ID: 37339843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of a GABAergic drug (Gamalate® B6): effects on behavior and cognition in young adults with borderline-to-mild intellectual developmental disabilities and ADHD.
    Novell R; Esteba-Castillo S; Rodriguez E
    Drugs Context; 2020; 9():212601. PubMed ID: 32158489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.
    Pringsheim T; Okun MS; Müller-Vahl K; Martino D; Jankovic J; Cavanna AE; Woods DW; Robinson M; Jarvie E; Roessner V; Oskoui M; Holler-Managan Y; Piacentini J
    Neurology; 2019 May; 92(19):896-906. PubMed ID: 31061208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risperidone for children and adolescents with autism spectrum disorder: a systematic review.
    Maneeton N; Maneeton B; Putthisri S; Woottiluk P; Narkpongphun A; Srisurapanont M
    Neuropsychiatr Dis Treat; 2018; 14():1811-1820. PubMed ID: 30022830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mindfulness-Based Program for Children with Autism Spectrum Disorder and Their Parents: Direct and Long-Term Improvements.
    Ridderinkhof A; de Bruin EI; Blom R; Bögels SM
    Mindfulness (N Y); 2018; 9(3):773-791. PubMed ID: 29875881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.
    Bergman H; Rathbone J; Agarwal V; Soares-Weiser K
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD000459. PubMed ID: 29409162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of Autism Spectrum Disorder in Children and Adolescents.
    DeFilippis M; Wagner KD
    Psychopharmacol Bull; 2016 Aug; 46(2):18-41. PubMed ID: 27738378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aripiprazole for autism spectrum disorders (ASD).
    Hirsch LE; Pringsheim T
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD009043. PubMed ID: 27344135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
    Aman M; Rettiganti M; Nagaraja HN; Hollway JA; McCracken J; McDougle CJ; Tierney E; Scahill L; Arnold LE; Hellings J; Posey DJ; Swiezy NB; Ghuman J; Grados M; Shah B; Vitiello B
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):482-93. PubMed ID: 26262903
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children.
    Kirino E
    Clin Med Insights Pediatr; 2014; 8():17-30. PubMed ID: 24932108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What's in the pipeline? Drugs in development for autism spectrum disorder.
    Sung M; Chin CH; Lim CG; Liew HS; Lim CS; Kashala E; Weng SJ
    Neuropsychiatr Dis Treat; 2014; 10():371-81. PubMed ID: 24591832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Not Available].
    Pringsheim T; Doja A; Belanger S; Patten S
    Paediatr Child Health; 2012 Oct; 17(Suppl B):22B-30B. PubMed ID: 24082814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.
    Politte LC; McDougle CJ
    Psychopharmacology (Berl); 2014 Mar; 231(6):1023-36. PubMed ID: 23552907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.